The novel GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has also demonstrated superior metabolic efficacy, including improvements in serum aminotransferase levels and liver fibrosis scores, in patients with T2DM and/or obesity [151]. Here, GLP1R is linked to obesity disorder.